Compound 113
Identifiers
- Canonical SMILES:
Cn1ncc2c1nc(-c1cccc(Br)c1)c1c2[nH]n(-c2cccc(F)c2)c1=O
- InChi:
InChI=1S/C20H13BrFN5O/c1-26-19-15(10-23-26)18-16(17(24-19)11-4-2-5-12(21)8-11)20(28)27(25-18)14-7-3-6-13(22)9-14/h2-10,25H,1H3
- InChiKey:
YQTWQTNGIZDXFE-UHFFFAOYSA-N
External search
Bibliography (1)
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
CD80 / CD28 | 7.66 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 437.03 g/mol | |||
HBA | 6 | |||
HBD | 1 | |||
HBA + HBD | 7 | |||
AlogP | 5.03 | |||
TPSA | 63.05 | |||
RB | 2 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.4914 | Riociguat | DB08931 | |
0.4775 | ATX-914 | DB12673 | |
0.4752 | Vericiguat | DB15456 | |
0.4721 | 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE | DB07218 | |
0.4717 | (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE | DB07595 | |
0.4538 | Merestinib | DB12381 | |
0.4522 | Dilmapimod | DB12140 | |
0.4481 | N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide | DB08349 | |
0.4444 | 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine | DB08534 | |
0.4410 | Neflamapimod | DB07138 | |
0.4410 | Ravoxertinib | DB15281 | |
0.4352 | TRIAZOLOPYRIMIDINE | DB04669 | |
0.4322 | ABT-288 | DB15192 | |
0.4316 | Tepotinib | DB15133 | |
0.4292 | 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine | DB07210 |